Lantheus Holdings (FRA:0L8) Interest Expense : €-18 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lantheus Holdings's interest expense for the three months ended in Mar. 2024 was € -4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-18 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lantheus Holdings's Operating Income for the three months ended in Mar. 2024 was € 92 Mil. Lantheus Holdings's Interest Expense for the three months ended in Mar. 2024 was € -4 Mil. Lantheus Holdings's Interest Coverage for the quarter that ended in Mar. 2024 was 20.66. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lantheus Holdings Interest Expense Historical Data

The historical data trend for Lantheus Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Interest Expense Chart

Lantheus Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-12.26

-7.79

-6.86

-6.78

-18.36

Lantheus Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-4.66	-4.55	-4.74	-4.62	-4.47

Lantheus Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-18 Mil.

Lantheus Holdings (FRA:0L8) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lantheus Holdings's Interest Expense for the three months ended in Mar. 2024 was €-4 Mil. Its Operating Income for the three months ended in Mar. 2024 was €92 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €567 Mil.

Lantheus Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	92.351	/	-4.47
	=	20.66

The higher the ratio, the stronger the company's financial strength is.

Lantheus Holdings (FRA:0L8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

LNTH:USA 0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines